HC Wainwright Lowers Jasper Therapeutics (NASDAQ:JSPR) Price Target to $40.00
Jasper Therapeutics (NASDAQ:JSPR – Get Free Report) had its price objective reduced by HC Wainwright from $60.00 to $40.00 in ...
Jane Street Group LLC Buys Shares of 13,354 Jasper Therapeutics, Inc. (NASDAQ:JSPR)
Jane Street Group LLC bought a new stake in Jasper Therapeutics, Inc. (NASDAQ:JSPR – Free Report) during the third quarter, ...
Investing5d
Jasper Therapeutics' SWOT analysis: briquilimab's potential in mast cell diseases
Jasper Therapeutics, Inc. (NASDAQ:JSPR), with a market capitalization of $105.23 million, is a clinical-stage biotechnology company focused on developing innovative treatments for mast cell ...
Jasper Therapeutics price target lowered to $48 from $68 at RBC Capital
RBC Capital analyst Gregory Renza lowered the firm’s price target on Jasper Therapeutics (JSPR) to $48 from $68 and keeps an Outperform rating ...
Healio1d
Patients with chronic spontaneous urticaria see well-controlled disease with briquilimab
Patients with chronic spontaneous urticaria experienced substantial reductions in hives and itch with briquilimab through 16 ...
Oppenheimer Sticks to Its Buy Rating for Voyager Therapeutics (VYGR)
In a report released today, Jay Olson from Oppenheimer maintained a Buy rating on Voyager Therapeutics (VYGR – Research Report), with a price ...
Investing5d
Jasper Therapeutics' SWOT analysis: briquilimab's potential in mast cell diseases
Jasper Therapeutics, Inc. (NASDAQ:JSPR), with a market capitalization of $105.23 million, is a clinical-stage biotechnology company focused on developing innovative treatments for mast cell-mediated ...
IWM ETF: Here’s why the Russell 2000 index is crashing
Explore why the iShares Russell 2000 ETF IWM has crashed hard this year amid the ongoing bond yield surge in the US.